Cocrystal Pharma Inc. | |
Stock Exchange | OTCBB |
EPS |
$1.49 |
Market Cap |
$70.51 M |
Shares Outstanding |
31.62 M |
Public Float |
9.68 M |
Address |
19805 North Creek Parkway Bothell Washington 98011 United States |
Employees | - |
Website | http://www.cocrystalpharma.com |
Updated | 07/08/2019 |
Cocrystal Pharma, Inc. is a clinical stage biotechnology company, which engages in discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of Hepatitis C. Phase 1b studies in Hepatitis C infected patients showed the largest reduction in viral load of any non-neoside inhibitor tested to date. |